Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Rainka

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2004
Copper-catalyzed asymmetric conjugate reduction as a route to novel beta-azaheterocyclic acid derivativesMatthew P Rainka, Yimon Aye, Stephen L Buchwald
Journal of the American Chemical Society|December 19, 2002
An annulative approach to highly substituted indoles: unusual effect of phenolic additives on the success of the arylation of ketone enolatesJennifer L Rutherford, Matthew P Rainka, Stephen L Buchwald
Journal of the American Chemical Society|February 14, 2002
A highly active Suzuki catalyst for the synthesis of sterically hindered biaryls: novel ligand coordinationJingjun Yin, Matthew P Rainka, Xiao-Xiang Zhang, et al.
Chemical Communications (Cambridge, England)|October 5, 2013
Highly selective electrocatalytic dehydrogenation at low applied potential catalyzed by an Ir organometallic complexPeter J Bonitatibus, Matthew P Rainka, Andrea J Peters, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 2012
Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivityMatthew E Voss, Matthew P Rainka, Mike Fleming, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2018
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitorTao Yu, Yonglian Zhang, Angela D Kerekes, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2010
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitorsDavid B Belanger, Michael J Williams, Patrick J Curran, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2004
Copper-catalyzed asymmetric conjugate reduction as a route to novel beta-azaheterocyclic acid derivativesMatthew P Rainka, Yimon Aye, Stephen L Buchwald
Journal of the American Chemical Society|December 19, 2002
An annulative approach to highly substituted indoles: unusual effect of phenolic additives on the success of the arylation of ketone enolatesJennifer L Rutherford, Matthew P Rainka, Stephen L Buchwald
Journal of the American Chemical Society|February 14, 2002
A highly active Suzuki catalyst for the synthesis of sterically hindered biaryls: novel ligand coordinationJingjun Yin, Matthew P Rainka, Xiao-Xiang Zhang, et al.
Chemical Communications (Cambridge, England)|October 5, 2013
Highly selective electrocatalytic dehydrogenation at low applied potential catalyzed by an Ir organometallic complexPeter J Bonitatibus, Matthew P Rainka, Andrea J Peters, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 2012
Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivityMatthew E Voss, Matthew P Rainka, Mike Fleming, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2018
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitorTao Yu, Yonglian Zhang, Angela D Kerekes, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2010
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitorsDavid B Belanger, Michael J Williams, Patrick J Curran, et al.
Pageof 1